Metabolic liver disease

Current Opinion in Gastroenterology

Volumn 17, Issue 3, 2001, Pages 221-231

  Schilsky, Michael L ^a   Mistry, Pramod ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALGLUCERASE; ALPHA GALACTOSIDASE; ALPHA GLUCOSIDASE; APOLIPOPROTEIN E; BETA GLUCOSIDASE; BIOCHEMICAL MARKER; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLUCOSYLCERAMIDASE; LEVO IDURONIDASE; MEMBRANE PROTEIN; PENICILLAMINE; SPHINGOLIPID ACTIVATOR PROTEIN 2; TRANSFERRIN RECEPTOR; TRIENTINE; ZINC ACETATE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CELL TRANSPORT; CLINICAL TRIAL; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LIVER DISEASE; LIVER TRANSPLANTATION; LYSOSOME STORAGE DISEASE; META ANALYSIS; METABOLIC DISORDER; MUCOPOLYSACCHARIDOSIS; NONHUMAN; PATHOGENESIS; REVIEW; SYMPTOMATOLOGY; WILSON DISEASE;

EID: 0035048562     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200105000-00005     Document Type: Review

References (44)

1. Diagnosis of Wilson disease: An experience over three decades
2. Wilson disease with superimposed autoimmune features: Report of two cases and review
3. Treatment of Wilson disease with zinc: XVII: Treatment during pregnancy
4. Wilson disease and pregnancy
5. Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins
6. The impact of apolipoprotein E genotypes on age and onset of symptoms and phenotypic expression in Wilson disease
7. Psychopathology in treated Wilson disease determined by means of CPRS expert and self-ratings
8. Role of ATP7B biliary copper excretion in a human hepatoma cell line and normal rat hepatocytes
9. Copper-induced apical trafficking of ATPTB in polarized hepatoma cells provides a mechanism for biliary copper excretion
10. Copper does not alter the intracellular distribution of ATP7B, a copper-transporting ATPase
11. Molecular cloning of transferrin receptor 2: A new member of the transferrin receptor-like family
12. Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis
13. Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo
14. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE
15. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter
16. A novel duodenal iron regulated transporter, IREG 1, implicated in basolateral transport of iron to the circulation
17. A novel mammalian iron regulated protein involved in intracellular iron metabolism
18. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis
19. The gene TFR2 is mutated in a new type of hemochromatosis mapping to 7q22
20. Population screening for hemochromatosis: A comparison of unbound iron binding capacity, transferrin saturation, and C282Y genotyping in 52,111 voluntary blood donors
21. Screening for heomchromatosis
22. Histological evaluation of iron in liver biopsies: Relation to HFE mutations
23. Liver transplantation in α1-antitrypsin deficiency
24. Liver transplantation for alpha-1-antitrypsin deficiency in children
25. Role of ubiquitin in proteasomal degradation of mutant alpha1-antitrypsin Z in the endoplasmin reticulum
26. Retention of mutant α1-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response
27. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (1α1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency
28. Clinical features of and recent advances in therapy for Fabry disease
29. Enzyme replacement therapy in Fabry disease: Results of a placebo-controlled phase 3 trial
30. Enzyme-replacement therapy in mucopolysaccharidosis 1
31. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients
32. Chemotherapy by slowing glucosphingolipid synthesis
33. Prevalence of lysosomal storage disorders
34. Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders
35. Massive hepatic fibrosis in Gaucher's disease: Clinico-pathological and radiological features
36. Abnormal lipid metabolism and high prevalence of gallstones in type 1 Gaucher disease
37. Analysis and classification of 304 mutant alleles in patients with Type 1 and Type 3 Gaucher disease
38. Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC)
39. A 25 year old man with severe coronary artery disease
40. Comparative efficacy of dose regimens in enzyme replacement therapy of type I gaucher disease
41. Commentary: Dosage-response in the treatment of gaucher disease by enzyme replacement therapy
42. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases
43. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
44. Fabry disease: Preclinical studies demonstrate the effectiveness of alpha-galactosidase a replacement in enzyme-deficient mice